(0.06%) 5 472.51 points
(0.08%) 39 145 points
(0.37%) 17 783 points
(0.04%) $80.86
(-3.66%) $2.66
(-0.78%) $2 312.70
(0.21%) $28.93
(3.64%) $1 022.30
(0.28%) $0.936
(0.70%) $10.68
(0.45%) $0.792
(-0.28%) $87.25
Live Chart Being Loaded With Signals
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies...
Stats | |
---|---|
今日成交量 | 15 193 |
平均成交量 | 230 496 |
市值 | 113.22M |
EPS | $-0.120 ( Q1 | 2024-05-07 ) |
下一个收益日期 | ( $0 ) 2024-08-06 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-3.55 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.0140 (0.77%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-06-13 | Grais Linda | Buy | 15 000 | Stock Option (Right to Buy) |
2024-06-13 | Clark Ian T | Buy | 15 000 | Stock Option (Right to Buy) |
2024-06-13 | Morrison Scott W | Buy | 15 000 | Stock Option (Right to Buy) |
2024-06-13 | Gould Terry P | Buy | 15 000 | Stock Option (Right to Buy) |
2024-06-13 | Thompson Peter A. | Buy | 15 000 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
93.20 |
Last 98 transactions |
Buy: 11 774 084 | Sell: 7 521 304 |
音量 相关性
Corvus Pharmaceuticals 相关性 - 货币/商品
Corvus Pharmaceuticals 财务报表
Annual | 2023 |
营收: | $0 |
毛利润: | $-151 000 (0.00 %) |
EPS: | $-0.560 |
FY | 2023 |
营收: | $0 |
毛利润: | $-151 000 (0.00 %) |
EPS: | $-0.560 |
FY | 2022 |
营收: | $0 |
毛利润: | $-367 000 (0.00 %) |
EPS: | $-1.080 |
FY | 2021 |
营收: | $0.00 |
毛利润: | $0.00 (0.00 %) |
EPS: | $-1.030 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Corvus Pharmaceuticals
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with either advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals for the development its pipeline of targeted investigational medicines. The company was incorporated in 2014 and is based in Burlingame, California.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。